PharmaShots

APRIL 14, 2023

Ocugen Reports Preliminary Results from the P-I/II Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Date: Apr 14, 2023 | Tags: Ocugen, OCU400, Retinitis Pigmentosa, Leber Congenital Amaurosis, Clinical Trial, P-I/II Trial Candesant Biomedical Receives the US FDA Clearance of Brella SweatControl Patch for Primary (..)

FDA 40

FDA 40

PharmaShots

MAY 26, 2023

Takeda and HUTCHMED's Fruquintinib Receives Priority Review from the US FDA to Treat Metastatic Colorectal Cancer Date: May 26, 2023 | Tags: Takeda, HUTCHMED, Fruquintinib, Metastatic Colorectal Cancer, Regulatory, Priority Review, US, FDA Gilead Receives EMA’s CHMP Positive Opinion to Extend the Use of Veklury (remdesivir) for COVID-19 Date: (..)

FDA 40

FDA 40

PharmaShots

MARCH 31, 2023

PDS Biotech to Initiate P-III Trial (VERSATILE-003) of PDS0101 + Keytruda (pembrolizumab) for Head and Neck Cancer Date: Mar 31, 2023 | Tags: PDS Biotech, PDS0101, Keytruda, pembrolizumab, Head, Neck Cancer, Clinical Trial, P-III, VERSATILE-003 Trial Omega Therapeutics Entered into a Clinical Supply Agreement with Roche to Evaluate OTX-2002 for Hepatocellular (..)

FDA 40

FDA 40

PharmaShots

FEBRUARY 17, 2023

Iveric Bio Reports the US FDA Acceptance of NDA and Granted Priority Review of Avacincaptad Pegol for Geographic Atrophy Date: Feb 17, 2023 | Tags: Iveric Bio, Avacincaptad Pegol, Geographic Atrophy, Regulatory, US, FDA, NDA, Priority Review ALX Oncology Reports the First Patient Dosing of Evorpacept in the P-I Study (ASPEN-07) for the Treatment of (..)

FDA 40

FDA Vaccines 40

PharmaShots

MAY 12, 2023

Sanofi Reports P-IIIb Trial (HARMONIE) Results of Nirsevimab for the Prevention of Hospitalizations due to RSV-Related LRTD Date: May 12, 2023 | Tags: Sanofi, Nirsevimab, RSV-Related LRTD, Clinical Trial, P-IIIb, HARMONIE Trial G1 Therapeutics Presents Preliminary Results from P-II Trial of Trilaciclib for Triple-Negative Breast Cancer at ESMO 2023 (..)

FDA 40

FDA Chemotherapy Immunization Hospitals 40

PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

FDA 40

FDA Immunization 40

European Pharmaceutical Review

MAY 22, 2023

A review by Swedish researchers has identified the benefits of smart contracts on blockchain platforms in the pharmaceutical supply chain and its role in combating counterfeit drugs. Additionally, real-time access to data is also available to patients to go through their clinical trials, as well as sponsors, which reduces the cost of trials.

93

93

pharmaphorum

APRIL 26, 2021

It also develops services to support the evolution of medical care and finding purposes in life, in collaboration with various research institutions and companies. In 2019 Cognitant and Addenbrook’s Hospital in Cambridge, UK piloted a programme that aimed to educate patients to improve adherence to rheumatoid arthritis medicines.

Hospitals 122

Hospitals 122

pharmaphorum

OCTOBER 3, 2022

‘Clearer’ data isn’t expected until 2024, with results from a late-stage phase 3 PHOENIX trial of around 600 patients due at that time. Following news of Relyvrio’s $158,000 annual price tag, both ALS advocates and outside observers have voiced outrage at the cost. ALS affects over 30,000 people in the US.

Insurance 52

Insurance FDA 52

Pharmaceutical Technology

JUNE 29, 2022

Others judge its success based on the fact that 95% of rare diseases still have no available therapies and patient needs remain unmet. Research and drug development for rare diseases has shifted from “niche” to conventional, aided by multiple drivers of growth in the field and favorable legislation.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies FDA 98

pharmaphorum

DECEMBER 23, 2021

The designation – which is awarded to therapies that could represent a significant improvement over standard of care in either efficacy, safety, or both – has been awarded on the strength of phase 1 results in patients with metastatic or locally advanced EGFR-mutated non-small cell lung cancer (NSCLC).

FDA 72

FDA Chemotherapy 72

pharmaphorum

JANUARY 18, 2022

Almirall and IRB Barcelona (the Institute for Research in Biomedicine), will conduct research using molecular glue degraders, a new approach to the skin diseases under scrutiny. Researchers at Almirall have identified several proteins whose abnormal function is associated with inflammatory immune skin diseases.

Immunization 52

Immunization 52

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Of these patients, seven have been treated at the recommended phase II dose (RP2D) and regimen.

Immunization 52

Immunization Hospitals Vaccines 52

pharmaphorum

AUGUST 17, 2020

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Virtual connections. Engagement channels.

Communication 97

Communication Insurance Packaging Pharmaceutical Companies 97

Roots Analysis

JANUARY 28, 2024

Velocity: Big Data needs to be handled promptly as businesses generate data at an unprecedented speed, driven by the growing adoption of Internet of Things (IoT), and technologies, such as RFID tags, sensors, and smart meters are used to deal with the high velocity of data in real-time. It is loosely arranged into categories using meta tags.

Health and Personal Care Stores 40

Health and Personal Care Stores Medical Records Hospitals 40

Pharmaceutical Technology

MAY 1, 2023

CTH-004 is developed by genetically altering patient T cells for inserting a chimeric antigen receptor (CAR) to target a marker (TAG-72) on ovarian cancer cells and delete genes which are involved in T cell function suppression. In animal models of ovarian cancer, it demonstrated promising results.

52

52

pharmaphorum

APRIL 5, 2022

Kimmtrak (tebentafusp) has been cleared to for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), mirroring its label in the US. Uveal melanoma is a rare cancer of the eye, which in the majority of patients is localised. ” Image by Pexels from Pixabay .

Labelling 52

Labelling Chemotherapy Immunization 52

The Checkup by Singlecare

DECEMBER 5, 2023

The #ozempic tag on TikTok has amassed over 1 billion views to date. This past year, statistics suggest that in certain cities of the United States, Ozempic patient volumes have increased by nearly 200%. In addition, the same study found that over half the patients taking Ozempic or a similar GLP-1 have a history of diabetes.

Insurance 105

Insurance Prescription Filling FDA Dosage 105

Pharmaceutical Technology

JULY 14, 2022

Historically, the pharmaceutical industry has failed to meet the needs of this patient population. The commercial investment required to research and develop an innovative drug, prove its safety and efficacy, and bring it to market is staggering. But where does this leave patients outside of these preferred markets?

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies Hospitals 59

The Checkup by Singlecare

NOVEMBER 2, 2023

So how do you know if they’re right for your patients (even those who aren’t diabetic)? GLP-1 drugs are effective: There is a substantial body of scientific research supporting the effectiveness of these medications for several weight-related health concerns. These are the benefits of GLP-1 drugs , beyond blood sugar control.

Insurance 52

Insurance FDA Adverse Reactions Hospitals 52

pharmaphorum

JUNE 8, 2021

The FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms” in approving Biogen’s Alzheimer’s disease drug Aduhelm. ICER points to brain swelling and potential bleeding seen in approximately 30% of patients treated with aducanumab. Broad label questioned.

FDA 98

FDA Labelling 98

pharmaphorum

JANUARY 21, 2022

“It has become clear that the medicines of the 20 th century, the so-called blockbuster era, are gradually being replaced by drugs designed for smaller groups, specific indication, and even for individual patients,” said Jo De C**k, CEO of Belgium’s National Institute for Health and Disability Insurance.

Insurance 52

Insurance Vaccines 52

pharmaphorum

JANUARY 31, 2023

This lack of trust in such a crucial industry can lead to decreased compliance, poor treatment adherence, and negative health outcomes for patients. With the recent rapid rollout of Covid-19 vaccines, many people have raised questions about whether adequate research was conducted on these vaccines before approval.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines Communication 52

pharmaphorum

JANUARY 5, 2021

The FDA’s breakthrough status is for tiragolumab plus Tecentriq is the first for a TIGIT drug, and covers the first-line treatment of patients with advanced-stage non-small cell lung cancer (NSCLC) that expresses high levels of PD-L1. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.

Chemotherapy 52

Chemotherapy Immunization FDA Labelling 52

pharmaphorum

JUNE 2, 2022

When asked by pharmaphorum why product sales are expected to be so high in this area, a spokesperson for Evaluate explained: “For many rare diseases, there is high unmet need which results in high levels of use of orphan products in the eligible patient groups, and these groups are often larger than anticipated once treatments become available.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies 52

PharmaShots

MARCH 9, 2023

Education: She is a Post Graduate Research Fellow in Gastroenterology and Immunology from Stanford University School of Medicine. Other Affiliations: Alison works as a visiting researcher at Imperial College's Institute of Biomedical Engineering. Designation: Chief Scientific Officer Previous company: Toumaz UK Ltd. (15

FDA 40

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 40

pharmaphorum

NOVEMBER 16, 2022

The advancements made in drug development over the last decade have seen the arrival of a number of treatments that offer one-time cures and more effective therapies for conditions in smaller patient populations. Advanced therapies have changed the treatment landscape for the industry and for patients. However, with a price tag of €1.58

131

131

pharmaphorum

NOVEMBER 28, 2022

The Linux Foundation AI & Data Foundation will house the software, which will now be available for any researcher to use for similar collaborative-data AI projects. “Researchers can now leverage privacy-preserving and secure federated learning software to drive cutting-edge collaborative medical research. .

Hospitals 72

Hospitals 72

Pharmaceutical Technology

JANUARY 27, 2023

Dr. James George, a research professor at the University of Oklahoma Health Sciences Center, said Cablivi “adds a new aspect to treatment, the prompt recovery of platelets and prompt resolution of transient neurologic symptoms”. Hlávka says healthcare providers often ask, “Should we only pay for some of the patients?

Documentation 52

Documentation Immunization Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JUNE 15, 2021

The adoption of New Science – a unique combination of the best in science and health technology that address significant unmet patient needs – is delivering more precise and effective treatments, but often at a higher price tag, according to new research. A new economic reality is challenging profitability .

Vaccines 90

Vaccines 90

Pharma Marketing Network

OCTOBER 4, 2020

Don ( PMN): Yeah and that might be a concern for some folks out there that who’s websites are supported by advertising because you’re relying upon another third-party that can be adding load time to a site when you’re when you’re add tags are loading.

Health and Personal Care Stores 52

Health and Personal Care Stores Packaging 52

pharmaphorum

OCTOBER 4, 2022

During the first stage of the initiative, more than 2,000 research papers were published, 49 clinical trials were carried out, and more than 30 patents were filed through the support of the US National Cancer Institute (NCI). Building a bank.

Documentation 105

Documentation Data Entry HIPAA Insurance 105

The Physician Pharmacist

SEPTEMBER 14, 2023

[link] The podcast is structured around several goals, including an overview of the medical school application process, a discussion of osteopathic vs. allopathic medical education, and insights into medical research and specialty choices. And they were the one kind of using their expertise to really guide the treatment of the patient.

Medical Schools 52

Medical Schools Hospitals Communication Patient Care 52

The Spirit Pharmacist

DECEMBER 2, 2021

However, psychedelic assisted therapy is resource intensive and will likely come with a price tag putting it out of reach of many persons that could benefit from such therapies. I'm also giving a talk for them this coming Thursday, December 9th at 6pm PST.

Health and Personal Care Stores 52

Health and Personal Care Stores Insurance Coverage Insurance Patient Care 52

The Checkup by Singlecare

JUNE 21, 2023

The condition causes higher levels of androgen hormone production, resulting in symptoms such as irregular menstrual cycles, acne, excess hair growth, cysts, skin tags, thinning hair, skin darkening, and infertility. The endocrine disorder affects up to 10% of women of reproductive age, 40%-80% of whom have obesity. Related: What is PCOS?

Insurance 98

Insurance FDA Compounding Compounding Pharmacies 98

pharmaphorum

FEBRUARY 26, 2021

Its founder, Dr Paul Janssen, is recognised as one of the most innovative and prolific pharmaceutical researchers of the 20th century. Dr Paul Janssen is recognised as one of the most innovative and prolific pharmaceutical researchers of the 20th century”. It was in 1961 that Belgium’s Janssen Pharmaceutica N.V. billion in cash.

Vaccines 126

Vaccines Labelling Communication 126

The Checkup by Singlecare

MARCH 7, 2024

Patients typically start on a low dose of 0.25 Ozempic cost Unfortunately, like many new drugs, Ozempic comes with a hefty price tag. Makhija says Novo Nordisk, the manufacturer of Ozempic, may offer coupons or rebates as well as patient resources and support for finding a lower cost of the medication.

Health and Personal Care Stores 52

Health and Personal Care Stores Insurance Packaging Insurance Coverage 52